Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 2/20 | 0.53 |
| ▸ | MEN1 | O00255 | 7/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.53 |
| ▸ | USP2 | O75604 | 2/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | CA1 | P00915 | 1/20 | 0.45 |
| ▸ | CA2 | P00918 | 1/20 | 0.45 |
| ▸ | MMP1 | P03956 | 1/20 | 0.45 |
| ▸ | MMP2 | P08253 | 1/20 | 0.45 |
| ▸ | MMP9 | P14780 | 1/20 | 0.45 |
| ▸ | MMP8 | P22894 | 1/20 | 0.45 |
| ▸ | MMP13 | P45452 | 1/20 | 0.45 |
| ▸ | BDKRB1 | P46663 | 1/20 | 0.44 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 2/20 | 0.43 |
| ▸ | TP53 | P04637 | 2/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2911827 | 0.85 | CA1 (0.48) | MEN1KMT2ALMNAMAPTCA1 | |
| SCHEMBL2912289 | 0.83 | ALDH1A1 (0.49) | MEN1KMT2ASMN1; SMN2LMNAMAPT | |
| SCHEMBL2908044 | 0.81 | CRHBP (0.45) | MEN1KMT2ALMNAMAPTHTT | |
| SCHEMBL2914646 | 0.81 | HTT (0.50) | SMN1; SMN2LMNAHTT | |
| SCHEMBL2913392 | 0.81 | CRHBP (0.47) | MEN1KMT2ALMNACA1CA2 | |
| SCHEMBL2911443 | 0.78 | PGR (0.42) | KMT2ASMN1; SMN2LMNAMAPTHTT | |
| SCHEMBL2911793 | 0.77 | KMT2A (0.57) | KMT2ALMNAMAPTHTTPOLB | |
| SCHEMBL2913005 | 0.76 | PDE4A (0.56) | KMT2ASMN1; SMN2LMNAHTTPOLB | |
| SCHEMBL2911655 | 0.75 | KMT2A (0.39) | KMT2ALMNAMAPTHTTTP53 | |
| SCHEMBL2914429 | 0.75 | KMT2A (0.49) | KMT2ASMN1; SMN2HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1263721-B1 | PHARMACEUTICAL COMPOSITIONS CONTAINING 3-AMINO-AZETIDINE DERIVATIVES, NOVEL DERIVATIVES AND PREPARATION THEREOF | AVENTIS PHARMA SA (FR) | 2010-08-25 | — | — | EP | claimed |
| US-20080221078-A1 | Use of a CB1 Antagonist for Treating Side Effects and Negative Symptoms of Schizophrenia | AVENTIS PHARMACEUTICALS INC. (US) | 2008-09-11 | — | — | US | claimed |
| EP-1962834-A2 | USE OF A CB1 ANTAGONIST FOR TREATING NEGATIVE SYMPTOMS OF SCHIZOPHRENIA | Aventis Pharmaceuticals Inc. (US) | 2008-09-03 | — | — | EP | claimed |
| WO-2007067617-A2 | USE OF A CB1 ANTAGONIST FOR TREATING NEGATIVE SYMPTOMS OF SCHIZOPHRENIA | AVENTIS PHARMACEUTICALS INC. (US) | 2007-06-14 | — | — | WO | claimed |
| EP-1328269-B1 | ASSOCIATION OF A CB1 RECEPTOR ANTAGONIST AND SIBUTRAMIN FOR TREATING OBESITY | AVENTIS PHARMA SA (FR) | 2004-05-26 | — | — | EP | claimed |
| EP-1328269-A2 | ASSOCIATION OF THE CB1 RECEPTOR ANTAGONIST AND A SIBUTRAMIN FOR TREATING OBESITY | Aventis Pharma S.A. (FR) | 2003-07-23 | — | — | EP | claimed |
| US-20020091114-A1 | Combination of a CB1 receptor antagonist and of sibutramine, the pharmaceutical compositions comprising them and their use in the treatment of obesity | AVENTIS PHARMA S.A. (FR) | 2002-07-11 | — | — | US | claimed |
| WO-2002028346-A2 | ASSOCIATION OF THE CB1 RECEPTOR ANTAGONIST AND SIBUTRAMIN, FOR TREATING OBESITY | AVENTIS PHARMA S.A. (FR) | 2002-04-11 | — | — | WO | claimed |
| EP-1263721-B1 | PHARMACEUTICAL COMPOSITIONS CONTAINING 3-AMINO-AZETIDINE DERIVATIVES, NOVEL DERIVATIVES AND PREPARATION THEREOF | AVENTIS PHARMA SA (FR) | 2010-08-25 | — | — | EP | disclosed |
| US-20080221078-A1 | Use of a CB1 Antagonist for Treating Side Effects and Negative Symptoms of Schizophrenia | AVENTIS PHARMACEUTICALS INC. (US) | 2008-09-11 | — | — | US | disclosed |
| EP-1962834-A2 | USE OF A CB1 ANTAGONIST FOR TREATING NEGATIVE SYMPTOMS OF SCHIZOPHRENIA | Aventis Pharmaceuticals Inc. (US) | 2008-09-03 | — | — | EP | disclosed |
| US-20080058381-A1 | COMBINATION OF A CB1 RECEPTOR ANTAGONIST AND OF SIBUTRAMINE, THE PHARMACEUTICAL COMPOSITIONS COMPRISING THEM AND THEIR USE IN THE TREATMENT OF OBESITY | AVENTIS PHARMA S.A. (FR) | 2008-03-06 | — | — | US | disclosed |
| US-20070197654-A1 | COMBINATION OF A CB1 RECEPTOR ANTAGONIST AND OF A PRODUCT WHICH ACTIVATES DOPAMINERGIC NEUROTRANSMISSION IN THE BRAIN, THE PHARMACEUTICAL COMPOSITIONS COMPRISING THEM AND THEIR USE IN THE TREATMENT OF PARKINSON'S DISEASE | AVENTIS PHARMA S.A. (FR) | 2007-08-23 | — | — | US | disclosed |
| WO-2007067617-A2 | USE OF A CB1 ANTAGONIST FOR TREATING NEGATIVE SYMPTOMS OF SCHIZOPHRENIA | AVENTIS PHARMACEUTICALS INC. (US) | 2007-06-14 | — | — | WO | disclosed |
| US-20030119810-A1 | Pharmaceutical compositions containing 3-aminoazetidine derivatives, novel derivatives and their preparation | AVENTIS PHARMA S.A. (FR) | 2003-06-26 | — | — | US | disclosed |
| US-6566356-B2 | 3-amido or 3-sulfonylamino azetidine compounds and their preparation; high affinity for cannabinoid receptor CB1 type, useful in treating central nervous system, immune, gastrointestinal or cardiovascular disorders, drug abuse | AVENTIS PHARMA S.A. (FR) | 2003-05-20 | — | — | US | disclosed |
| EP-1263721-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING 3-AMINO-AZETIDINE DERIVATIVES, NOVEL DERIVATIVES AND PREPARATION THEREOF | Aventis Pharma S.A. (FR) | 2002-12-11 | — | — | EP | disclosed |
| US-20020091114-A1 | Combination of a CB1 receptor antagonist and of sibutramine, the pharmaceutical compositions comprising them and their use in the treatment of obesity | AVENTIS PHARMA S.A. (FR) | 2002-07-11 | — | — | US | disclosed |
| US-20020019383-A1 | Pharmaceutical compositions containing 3-aminoazetidine derivatives, novel derivatives and their preparation | AVENTIS PHARMA S.A. (FR) | 2002-02-14 | — | — | US | disclosed |
| WO-2001064633-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING 3-AMINO-AZETIDINE DERIVATIVES, NOVEL DERIVATIVES AND PREPARATION THEREOF | AVENTIS PHARMA S.A. (FR) | 2001-09-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080058381-A1 | COMBINATION OF A CB1 RECEPTOR ANTAGONIST AND OF SIBUTRAMINE, THE PHARMACEUTICAL COMPOSITIONS COMPRISING THEM AND THEIR USE IN THE TREATMENT OF OBESITY | CNR2, CNR1, GPR119 | IDO1 625/4885MEN1 3096/4885KMT2A 1186/4885 |
| US-20020019383-A1 | Pharmaceutical compositions containing 3-aminoazetidine derivatives, novel derivatives and their preparation | HRH2, ALK, HRH1 | IDO1 1534/4885MEN1 4647/4885KMT2A 1373/4885 |
| US-20030119810-A1 | Pharmaceutical compositions containing 3-aminoazetidine derivatives, novel derivatives and their preparation | ALK, HRH2, HRH1 | IDO1 1582/4885MEN1 4676/4885KMT2A 1544/4885 |
| US-20020091114-A1 | Combination of a CB1 receptor antagonist and of sibutramine, the pharmaceutical compositions comprising them and their use in the treatment of obesity | CNR2, CNR1, GPR119 | IDO1 625/4885MEN1 3096/4885KMT2A 1186/4885 |
| US-20070197654-A1 | COMBINATION OF A CB1 RECEPTOR ANTAGONIST AND OF A PRODUCT WHICH ACTIVATES DOPAMINERGIC NEUROTRANSMISSION IN THE BRAIN, THE PHARMACEUTICAL COMPOSITIONS COMPRISING THEM AND THEIR USE IN THE TREATMENT OF PARKINSON'S DISEASE | CNR1, CNR2, GPR18 | IDO1 1279/4885MEN1 3124/4885KMT2A 3354/4885 |
| US-20080221078-A1 | Use of a CB1 Antagonist for Treating Side Effects and Negative Symptoms of Schizophrenia | CNR1, CNR2, GPR139 | IDO1 1528/4885MEN1 4608/4885KMT2A 1060/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.